- Home
- EVV vs IMNM Comparison
EVV vs IMNM Comparison
Compare EVV & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- IMNM
- Stock Information
- Founded
- EVV 2003
- IMNM 2006
- Country
- EVV United States
- IMNM United States
- Employees
- EVV N/A
- IMNM N/A
- Industry
- EVV Finance/Investors Services
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- EVV Finance
- IMNM Health Care
- Exchange
- EVV Nasdaq
- IMNM Nasdaq
- Market Cap
- EVV 1.2B
- IMNM 1.2B
- IPO Year
- EVV N/A
- IMNM 2020
- Fundamental
- Price
- EVV $9.99
- IMNM $17.16
- Analyst Decision
- EVV
- IMNM Strong Buy
- Analyst Count
- EVV 0
- IMNM 9
- Target Price
- EVV N/A
- IMNM $24.89
- AVG Volume (30 Days)
- EVV 323.7K
- IMNM 1.4M
- Earning Date
- EVV 01-01-0001
- IMNM 11-06-2025
- Dividend Yield
- EVV 9.66%
- IMNM N/A
- EPS Growth
- EVV N/A
- IMNM N/A
- EPS
- EVV N/A
- IMNM N/A
- Revenue
- EVV N/A
- IMNM $9,679,000.00
- Revenue This Year
- EVV N/A
- IMNM N/A
- Revenue Next Year
- EVV N/A
- IMNM $85.36
- P/E Ratio
- EVV N/A
- IMNM N/A
- Revenue Growth
- EVV N/A
- IMNM N/A
- 52 Week Low
- EVV $8.52
- IMNM $5.15
- 52 Week High
- EVV $10.07
- IMNM $18.46
- Technical
- Relative Strength Index (RSI)
- EVV 41.00
- IMNM 59.97
- Support Level
- EVV $10.02
- IMNM $14.64
- Resistance Level
- EVV $10.14
- IMNM $17.94
- Average True Range (ATR)
- EVV 0.05
- IMNM 1.21
- MACD
- EVV 0.00
- IMNM -0.05
- Stochastic Oscillator
- EVV 5.88
- IMNM 67.63
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.